Celltrion Signs an Exclusive Co-Marketing Agreement with Juno in Australia

Celltrion Reports Results of CT-P10 (rituximab, biosimilar) in P-III for Advance Follicular Lymphoma (AFL)


  • Juno to provide sales promotion and hospital contracting services to Australian Hospital market customers and will co-market Herzuma (biosimilar, trastuzumab) and Truxima (biosimilar, rituximab) with Celltrion in Australia
  •  The focus of the agreement is to market globally biosimilar brands to Australian Healthcare professionals and patients
  • Herzuma (CT-P6, biosimilar, trastuzumab) is a mAb targeting the extracellular domain of HER2 receptor and has received MFDS, EC and the FDA’s approval in Jan’2014, Feb’2018 and Dec’2018 respectively. Truxima is a mAb (CT-P10, biosimilar, rituximab) is a mAb approved in Korea in 2016, EU in Feb,2017 and is a novel biosimilar approved by Health Canada for NHL, CLL and RA

Click here to­ read full press release/ article | Ref: Juno Pharmaceuticals | Image: Celltrion